Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease

Last updated: November 19, 2023
Sponsor: Yanfeng Hou
Overall Status: Active - Recruiting

Phase

N/A

Condition

Myositis

Lupus

Connective Tissue Diseases

Treatment

N/A

Clinical Study ID

NCT06149039
YXH2022ZX03223
  • Ages 18-70
  • All Genders

Study Summary

To detect the changes of lymphocyte subsets in peripheral blood of non-myopathic dermatomyositis with pulmonary interstitial disease, classical dermatomyositis with pulmonary interstitial disease, rheumatism with non-inflammatory myopathy with pulmonary interstitial disease and healthy adults among the 4 groups, and to detect the related cytokines secreted by lymphocyte subsets Th1,Th2 and Th17. Clinical features, distribution of peripheral lymphocyte subsets ratio and related cytokine content secreted by each lymphocyte subset were analyzed in each group, so as to explore the pathogenesis characteristics of nonmyopathic dermatomyositis complicated with pulmonary interstitial disease, in order to facilitate clinical guidance for diagnosis and treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. The experimental group met the diagnostic criteria of Sontheimer and was diagnosed asCADM with pulmonary interstitial disease.
  2. Control group 1: The diagnosis was consistent with the diagnostic criteria of Bohanand Perter classification system, and it was confirmed that dermatomyositis wascombined with pulmonary interstitial disease;
  3. Control group 2: The diagnosis meets the classification criteria of systemic lupuserythematosus revised by the American College of Rheumatology (ACR) in 1997 and isconfirmed as systemic lupus erythematosus combined with pulmonary interstitialdisease, or the diagnosis meets the diagnostic criteria of rheumatoid arthritisintroduced by ACR in 1987 or ACR in 2010 and is confirmed as rheumatoid arthritiscombined with pulmonary interstitial disease.
  4. Age 18-70 years old;
  5. Have a good understanding of their own illness and physical condition, haveself-knowledge, can communicate well with others;
  6. Voluntarily join the study, understand the significance of the experiment and theindicators to be measured, and sign the informed consent.

Exclusion

Exclusion Criteria:

  1. Severe infection: fever, cough, phlegm, sore throat, abdominal pain, diarrhea,carbuncle and other skin and soft tissue infection and other clinical manifestations,blood routine white blood cell count beyond the normal range (10×109/L);
  2. Severe cardiovascular disease: including chronic heart dysfunction grade 3 or aboveand various arrhythmias;
  3. Infectious diseases: hepatitis active stage, AIDS, syphilis, etc.
  4. Tumor markers of patients suggest the possibility of tumor.
  5. Patients with neuromuscular disease, inflammatory bowel disease, functionalgastrointestinal disease;
  6. The patient has other connective tissue diseases or disorders.

Study Design

Total Participants: 120
Study Start date:
April 01, 2023
Estimated Completion Date:
June 30, 2024

Connect with a study center

  • Yanfeng Hou

    Jinan, Shandong 250000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.